Hypogonadism in adolescent females: New insights and rationale supporting the use of physiologic regimens to induce puberty

Pediatric Endocrinology Reviews

Volumn 2, Issue 4, 2005, Pages 645-652

  Rubin, Karen ^a,b  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b Farmington   (United States)

Author keywords

Estradiol (e2); Final adult height (FAH); Growth hormone insulin like growth factor 1 axis (GH IGF1 axis); Hypergonadotropic hypogonadism (HyperH); Hypogonadotropic hypogonadism (HypoH); Peak bone mass (PBM)

Indexed keywords

AUTOIMMUNE REGULATOR PROTEIN; C REACTIVE PROTEIN; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; FOLLITROPIN; FOLLITROPIN RECEPTOR; GESTAGEN; GLUCOSE; GONADORELIN; GROWTH HORMONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOPHYSIS HORMONE; INTERLEUKIN 6; LEPTIN; LEPTIN RECEPTOR; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; MEDROXYPROGESTERONE ACETATE; NUCLEAR RECEPTOR DAX 1; PROGESTERONE; PROVERACYCRIN; SEX HORMONE; SOMATOMEDIN C; TRANSCRIPTION FACTOR PIT 1; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT DISEASE; BODY COMPOSITION; DELAYED PUBERTY; DIFFERENTIAL DIAGNOSIS; DRUG DOSE REGIMEN; DRUG EFFECT; GENE IDENTIFICATION; GENE MUTATION; GLUCOSE METABOLISM; HORMONAL REGULATION; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; HYPERGONADOTROPIC HYPOGONADISM; HYPOGONADISM; HYPOGONADOTROPIC HYPOGONADISM; LIPID METABOLISM; LOW DRUG DOSE; OOCYTE DEVELOPMENT; OVULATION; PUBERTY; PULSATILE HORMONE RELEASE; REVIEW; SIDE EFFECT;

ADOLESCENT; ENDOCRINOLOGY; FEMALE; HUMANS; HYPOGONADISM; PUBERTY;

EID: 20444371911     PISSN: 15654753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Marshall W, Tanner J. Variations in pattern of pubertal changes in girls. Arch Dis Child 1969;44:291-303
2. Lee P. Normal ages of pubertal events among American males and females. J Adolesc Health Care 1980;1:26-29
3. Roche A, Wellens R, Altie K, Siervogel R. The timing of sexual maturation in a group of US white youths. J Pediatric Endocrinol Metab 1995;8:11-18
4. Herman-Giddens M, Slora E, Wasserman R, Bourdony C, Bhapkar M, Hasemeier C. Secondary sexual characteristics and menses in young girls seen in office practice: a study from the Pediatric Research Office Settings Network. Pediatrics 1997;99:505-512
5. Reindollar R, Tho S, McDonough P. Delayed Puberty; An updated study of 326 Patients. 1989 Transactions of the American Gynecological and Obstetrical Society. 1989;8:146-162
6. Sedlmeyer I, Palmert M. Delayed puberty: Analysis of a large case series from an academic center. J Clin Endo Metab 2002;87(4):1613-1620
7. Rugarli E, Ballabino A. Kallmann Syndrome: From Genetics to Neurobiology. JAMA 1993;270:2713-2716
8. Layman L. Molecular Basis of Human Hypogonadotropic Hypogonadism. Mol Genet Metab 1999;68:191-199
9. Tabarin AAJ, Recan D, Bex V, Bertagna X, Christin-Maitre S, Ito M, Jameson J, Bouchard P. A novel mutation in DAXI causes delayed onset adrenal insufficiency and incomplete hypogonadotropic hypogonadism. J Clin Invest 2000;105:321-328
10. Merke D, Tajima T, Baron J, Cutler G. Hypogonadotropic hypogonadism in a female caused by an x-linked recessive mutation in the DAX-1 gene. N Engl J Med 1999;340:1248-1252
11. DeRoux N, Young J, Misrahi M, Genet R, Chanson P, Schaison G, Milgram E. A family with hypogonadotropic hypogonadism and mutations in the gonadotropin-releasing hormone receptor. N. Engl J Med 1997;337:1597-1602
12. Layman L, Cohen D, Jin M, Xie T, Li Z, Reindollar R, Bolbolan S, Bick D, Sherins R, Duck L, Musgrove L, Sellers J, Neill J. Mutations in gonadotropin-releasing hormone receptor gene cause hypogonadotropic hypogonadism. Nat Genet 1998;18:14-15
13. Beranova M, Oliveira L, Bedecarrats G, Schipani E, Vallejo M, Ammini A, Quintos J, Hall J, Martin K, Hayes F, Pitteloud N, Kaiser U, Crowley W, Seminara S. Prevalence, phenotypic spectrum, and modes of inheritance of gonadotropin-releasing hormone receptor mutation sin idiopathic hypogonadotropic hypogonadism. J Clin Endo Metab 2001;86:1580-1588
14. Seminara S, Beranova M, Oliveira L, Martin K, Crowley Jr W, Hall J. Successful use of pulsatile gonadotropin-releasing hormone (GnRH) for ovulation induction and pregnancy in a patient with GnRH receptor mutations. J Clin Endo Metab 2000;85:556-562
15. Thomas P, Dattani M, Brickman J, McNay D, Warne G, Zacharin M, Cameron F, Hurst J, Woods K, Dunger D, Stanhope R, Forrest S, Robinson I, Beddrington R. Heterozygous HESXI mutations associated with isolated congenital pituitary hypoplasia and septo-optic dysplasia. Hum Mol Genet 2001;10:39-45
16. Netchine I, Sobrier M, Krude H, Schnabel D, Maghnie M, Marcos E, Duriez B, Cacheux V, Moers A, Goossens M, Gruters A, Amselem S. Mutations in LHX3 result in a new syndrome revealed by combined pituitary hormone deficiency. Nat Genet 2000;25:182-186
17. Wu W, Cogan J, Pfaffle R, Dasen J, Frisch H, O'Connell, S, Flynn S, Brown M, Mullis P, Parks J, Phillips 3rd J, Rosenfeld M. Mutations in PROP1 cause familial combined pituitary hormone deficiency, 1998;18:147-149
18. Fluck, C, Deladoey J, Rutishauser K, Eble A, Marti U, Mullis P. Phenotypic variability in familial combined pituitary hormone deficiency caused by a PROP1 gene mutation resulting in the substitution of Arg - < Cys at codon 120 (R120C). J Clin Endo Metab 1998;83:3727-3734
19. Matthews C, Borgato S, Beck-Peccoz P, Adams M, Tone Y, Gambino G, Casagrande S, Tedeshini G, Benedetti A, Chatterjee V. Primary amenorrhea and infertility due to a mutation in the B-subunit of follicle stimulating hormone. Nat Genet 1993;5:83-86
20. Layman L, Lee E, Peak D, Namnoun A, Vu K, Van Lingen B, Gray M, McDonough P, Reindollar R, Jameson J. Delayed puberty and hypogonadism caused by mutations in the follicle-stimulating hormone B subunit gene. N Engl J Med 1997;337:607-611
21. Layman L. Mutations in human gonadotropin genes and their physiologic significance in puberty and reproduction. Fertil Steril 1999;71:201-218
22. O'Rahilly S, Gray H, Humphreys PJ, Krook A, Polonsky KS, White A, Gibson S, Taylor K, Cam C. Impaired processing of prohormones associated with abnormalities of glucose homeostasis and adrenal function. N Engl J Med 1995;333:1386-1390
23. Jackson R, Creemers J, Ohagi S, Raffin-Sanson M, Sanders L, Montaque C, Hutton J, O'Rahilly S. Obesity and impaired prohormone processing associated with mutations in the human convertase 1 gene. Nat Genet 1997;16:303-306
24. Strobel A, Issad T, Camoin L, Ozata M, Strosbers A. A leptin missense mutation associated with hypogonadism and morbid obesity. Nat Genet 1998;18:213-215
25. Clement K, Vaisse C, Lablou N, Cabrol S, Pelloux V, Cassuto D, Gourmelen M, Dina C, Chambaz J, Lacorte J, Basdevant A, Bougneres P, Lebouc Y, Fraguel P, Guy-Grand B. A mutation in the human leptin receptor gene causes obesity and pituitary dysturohan. Nature 1998;392:398-401
26. Faraoqi I, Jebb S, Lansmack G, Lawrence E, Cheetham CH, Prentice AM, Hushes IA, McCamish MA, O'Rahilly S. Effects of recombinant lepkin therapy in a child with congenital leptin deficiency. N Engl J Med 1999;341:879-884
27. Aittomaki K, Lucena JL, Pakarinen P, Sistonen P, Tapanainen J, Gromoll J, Kaskikari R, Sankila EM, Lehvaslaihu H, Engel AR, et al. Mutation in the follicle-stimulating hormone receptor gene causes hereditary hypergonadotropic ovarian failure. Cell 1995;82:952-968
28. Aittomaki K, Herva R, Stenman UH, Juntunen K, Ylostalo P, Hovatta O, de la Chapelle A. Clinical Features of primary ovarian failure caused by a point mutation in the follicle-stimulating hormone receptor gene. J Clin Endocrinol Metab 1996;81:3722-3726
29. Beau I, Touraine P, Meduri G, Gougeon A, Desroches A, Matuchansky C, Milsrom E, Kuttenn F, Misrati M. A novel phenotype related to partial loss of function mutations of the follicle-stimulating hormone receptor. J Clin Invest 1998;102:1352-1359
30. Latronico A, Anasti J, Arnhold JP, Rapaport R, Mendonca BB, Bloise W, Castro M, Tsigos C, CHrousos GP. Testicular and ovarian resistance to luteinizing hormone receptor caused by inactivating mutations of the luteinizing hormone receptor gene. N Engl J Med 1996;334:507-512
31. Toledo S, Brunner HG, Kraaij R, Post M, Dahia PL, Hayashida CY, Kremer H, Themmen AP. An inactivating mutation of the luteinizing hormone-receptor causes amenorrhea in a 46, xx female. J Clin Endo Metab 1996;81:3850-3854
32. Stavrou S, Zhu YS, Cai LQ, Katz MD, Herrera C, Defillo-Ricart M, Imperato-McGinley J. A novel mutation of the human luteinizing hormone receptor in 46 xy and 46 xx sisters. J Clin Endo Metab 1998;83:2091-2098
33. Kumar P, Laloraya M, She T. Population genetics and functions of the autoimmune regulator (AIRE). Endocrinol and Metab Clin North Am 2002;31(2):321-338
34. Ross J, Cassorla F, Skerda M, Valk I, Loriaux D, Cutler GJ. A preliminary study of the effect of estrogen dose on growth in Turner's Syndrome. N Engl J Med 1983;309:1104-1106
35. Cheranausek S, Attie KM, Cara JF, Rosenfield RG, France J. Growth hormone therapy of Turner Syndrome: The impact of age of estrogen replacement on final height. Genentech Collaborative Study Group. J Clin Endo Metab 2000;85:2439-2445
36. Rosenfield R, Perovic N, Devine N, Mauras N, Moshans T, Root A, Sy JP. Optimizing estrogen replacement treatment in Turner Syndrome. Pediatrics 1998;102(2):486-488
37. Van Pareren Y, Keizer-Schrama S, Strijenen T, Sas T, Jansen M, et al. Final height in girls with Turner Syndrome after long-term growth hormone treatment in three dosages and low dose estrogen. J Clin Endo Metab 2003;88:1119-1125
38. Ankarberg-Lindgren C, Elfuing M, Wikland KA, Norjavaara E. Nocturnal application of transdermal estradiol patches produces levels of estradiol that mimic those seen at the onset of spontaneous puberty in girls. J Clin Endo Metab 2001;86:3039-3044
39. Piippo S, Lenko H, Kainulainen P, Sipila I. Use of Percutaneous Estrogen Gel for Induction of Puberty in Girls with Turner Syndrome. J Clini 2004;89:3241-3247
40. Cook D, Ludlam WH, Cook MB. Route of estrogen administration helps to determine growth hormone (GH) replacement dose in GH-defident adults. J Clin Endo Metab 1999;84:3956-3966
41. Janssen Y, Helmerhorst F, Frolich M, Roelfsema F. A switch from oral (2 mg/day) to transdermal (50 mg/day) 17-B-estradiol therapy increases serum insulin-like growth factor levels in recombinant human growth hormone-substituted women with GH deficiency. J Clin Endo Metab 2000;85:464-467
42. Duursma S, Bijlsma JWJ, Van Paassen HC, Van Buui-Offers SC, Skottner-Lunoin A. Changes in serum somatomedin and growth hormone concentrations after 3 weeks of estrogen substitution in post-menopausal women; a pilot study. Acta Endcrinol 1984;106:527-531
43. Dawson-Hushes B, Stern D, Goldman J, Reichtin S. Regulation of growth hormone and somatomedin-C secretion in post-menopausal women: effect of physiological estrogen replacement. J Clin Endo Metab 1986;63:424-432
44. Capeland K. Effects of acute high dose and chronic low dose estrogen on plasma somatomedin C and growth in patients with Turner Syndrome. J Clin Endo Metab 1988;66:1278-1282
45. Leung K, Johannsson G, Leong GM, Ho K. Estrogen regulation of growth hormone action. Endocrine Reviews 2004;25:693-721
46. Kelly J, Rajkovic IA, O'Sullivan AJ, Sernia C, Ho KKY. Effects of different estrogen formulations on insulin-like growth factor-1, growth hormone and growth hormone binding protein in post-menopausal women. Clin Endocrinol 1993;39:561-567
47. Friend KE, Hartman ML, Pezzoli S, Clasey J, Thorner M, Both oral and transdermal estrogen increases growth hormone release in post-menopausal women. J Clin Endo Metab 1996;81:2250-2256
48. Yigit S, Onyirimba M, Gendreau P, Lerer T, Rubin K. Effects of transdermal vs. oral estradiol on growth factors and markers of bone turnover in young adults with Turner Syndrome. J of Bone and Mineral Research 2004;19(1):5320
49. Ho K, Weissberser AJ. Impact of short-term estrogen administration on growth hormone secretion and action: distinct route-dependent effects on connective and bone tissue metabolism. J Bone Miner Res 1992;7:821-827
50. O'Sullivan A, Ho KKY. A comparison of the effects of oral and transdermal estrogen replacement on insulin sensitivity in postmenppausal women. J Clin Endo Metab 1995;80:1783-1788
51. Perseghin G, Scifo P, Pasliato E, Battezzati A, Benedini S, Soldini L, Testolin G, Del Maschio A, Luzi L. Gender factors affect fatty acids - induced insulin resistance in non-obese humans: effects of oral steroidal contraception. J Clin Endo Metab 2001;86:3188-3196
52. Clausen J, Borch-Johnsen K, Ibsen H, Bergman RN, Hougaard P, Winther K, Pedersen O. Insulin sensitivity index, acute insulin response, and glucose effectiveness in a population-based sample of 380 young healthy Caucasians. Analysis of the impact of gender, body fat, physical fitness, and life-style factors. J Clin Invest 1996;98:1195-1209
53. Godsland I, Walton C, Felton C, Proudler A, Patel A, Wynn V. Insulin resistance, secretion, and metabolism in users of oral contraceptives. J Clin Endo Metab 1992;74:64-70
54. O'Sullivan A, Crampton L, Feund J, Ho KKY. Route of estrogen replacement confers divergent effects on energy metabolism and body composition in post-menopausal women. J Clin Invest 1998;102:1035-1040
55. Walsh B, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM. Effects of post-menopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991;325:1196-1204
56. Seed M. Sex hormones, lipoproteins, and cardiovascular risk. Atherosclerosis 1990;1990:1-7
57. Sacks F, Walsh BW. Sex hormones and lipoprotein metabolism. Curr Opin Lipidol 1994;5:236-240
58. Godsland I. Effects of postmenopausal hormone replacement on lipid, lipoprotein and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Fertil Steril 2001;75:898-915
59. Ridker P, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-843
60. Pfeilschifter J, Koditz R, Pfohl M, Schatz H. Changes in pro-inflammatory cytokine activity after menopause. Endocrine Reviews 2002;23:90-119
61. Venkavaara S, Silveira A, Hakala-Ala-Pietila T, Virkamaki A, Hovatta O, Hamsten A, Taskinen MR, Yki-Jarvinen H. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 2001;85:619-625
62. Kiess W, Conway G, Ritzen M, Rosenfield R, Bernasconi S, Juul A, Van Pareren Y, de Muinck Keizer-Schrama SM, Bourgiugnon JP. Induction of puberty in the hypogonadal girl - practices and attitudes of pediatric endocrinologists in Europe. Horm Res 2002;57(1-2):66-71
63. Drobac S, Rosenfield RL, Rubin K, Rogol A. Pubertal hormone replacement treatment attitudes and practices of Pediatric Endocrinologists in the United States (Submitted for publication), 2005.